FibroBiologics (FBLG) Competitors $0.62 +0.03 (+5.30%) Closing price 09/2/2025 04:00 PM EasternExtended Trading$0.61 -0.01 (-1.83%) As of 09/2/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock FBLG vs. ANIX, SRZN, CRDL, XBIT, VTGN, VIRI, IMUX, ABOS, EPIX, and CELUShould you be buying FibroBiologics stock or one of its competitors? The main competitors of FibroBiologics include Anixa Biosciences (ANIX), Surrozen (SRZN), Cardiol Therapeutics (CRDL), XBiotech (XBIT), VistaGen Therapeutics (VTGN), Virios Therapeutics (VIRI), Immunic (IMUX), Acumen Pharmaceuticals (ABOS), ESSA Pharma (EPIX), and Celularity (CELU). These companies are all part of the "pharmaceutical products" industry. FibroBiologics vs. Its Competitors Anixa Biosciences Surrozen Cardiol Therapeutics XBiotech VistaGen Therapeutics Virios Therapeutics Immunic Acumen Pharmaceuticals ESSA Pharma Celularity Anixa Biosciences (NASDAQ:ANIX) and FibroBiologics (NASDAQ:FBLG) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends. Which has more risk & volatility, ANIX or FBLG? Anixa Biosciences has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500. Comparatively, FibroBiologics has a beta of -0.73, indicating that its share price is 173% less volatile than the S&P 500. Which has higher valuation and earnings, ANIX or FBLG? FibroBiologics has lower revenue, but higher earnings than Anixa Biosciences. Anixa Biosciences is trading at a lower price-to-earnings ratio than FibroBiologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnixa Biosciences$210K473.95-$12.55M-$0.38-8.13FibroBiologicsN/AN/A-$11.16M-$0.36-1.73 Do institutionals and insiders believe in ANIX or FBLG? 29.1% of Anixa Biosciences shares are owned by institutional investors. 25.3% of Anixa Biosciences shares are owned by insiders. Comparatively, 20.8% of FibroBiologics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is ANIX or FBLG more profitable? Anixa Biosciences' return on equity of -68.17% beat FibroBiologics' return on equity.Company Net Margins Return on Equity Return on Assets Anixa BiosciencesN/A -68.17% -60.38% FibroBiologics N/A -710.25%-118.02% Do analysts recommend ANIX or FBLG? Anixa Biosciences presently has a consensus price target of $9.00, indicating a potential upside of 191.26%. FibroBiologics has a consensus price target of $13.00, indicating a potential upside of 1,992.05%. Given FibroBiologics' stronger consensus rating and higher possible upside, analysts clearly believe FibroBiologics is more favorable than Anixa Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anixa Biosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00FibroBiologics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Does the media favor ANIX or FBLG? In the previous week, Anixa Biosciences and Anixa Biosciences both had 2 articles in the media. FibroBiologics' average media sentiment score of 0.63 beat Anixa Biosciences' score of 0.62 indicating that FibroBiologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anixa Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive FibroBiologics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryFibroBiologics beats Anixa Biosciences on 8 of the 14 factors compared between the two stocks. Get FibroBiologics News Delivered to You Automatically Sign up to receive the latest news and ratings for FBLG and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FBLG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FBLG vs. The Competition Export to ExcelMetricFibroBiologicsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$24.72M$3.12B$5.75B$9.77BDividend YieldN/A2.28%6.66%4.50%P/E Ratio-1.7320.8682.5826.39Price / SalesN/A396.75535.42110.55Price / CashN/A43.5325.7028.92Price / Book31.078.1011.196.58Net Income-$11.16M-$53.35M$3.28B$265.84M7 Day Performance3.60%-0.29%-0.19%-0.26%1 Month Performance-4.19%9.18%8.36%5.82%1 Year Performance-61.88%10.11%55.89%22.47% FibroBiologics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FBLGFibroBiologics2.9266 of 5 stars$0.62+5.3%$13.00+1,992.1%-61.6%$24.72MN/A-1.7310News CoverageANIXAnixa Biosciences2.8792 of 5 stars$3.00-2.0%$9.00+200.0%-7.5%$98.57MN/A-7.895Upcoming EarningsSRZNSurrozen2.7684 of 5 stars$11.37-1.1%$38.50+238.6%+15.8%$98.47M$10.65M-0.7980News CoveragePositive NewsCRDLCardiol Therapeutics2.8125 of 5 stars$1.14-2.6%$8.00+601.8%-43.3%$97.94MN/A-3.3520Positive NewsXBITXBiotech1.7941 of 5 stars$3.20flatN/A-52.8%$97.56M$4.01M-3.48100Short Interest ↓VTGNVistaGen Therapeutics1.2174 of 5 stars$3.03-4.4%N/A+0.9%$97.26M$490K-1.7040News CoveragePositive NewsVIRIVirios Therapeutics0.1138 of 5 stars$4.95+0.2%$5.00+1.0%+2,456.7%$95.30MN/A-18.335News CoverageGap UpIMUXImmunic2.6058 of 5 stars$0.88-7.7%$7.50+755.4%-47.1%$93.72MN/A-0.7170ABOSAcumen Pharmaceuticals2.8627 of 5 stars$1.51-1.3%$7.00+363.6%-50.4%$92.68MN/A-0.6620EPIXESSA Pharma3.5638 of 5 stars$0.78-59.4%$2.00+155.1%-95.7%$91.31MN/A-1.4050Dividend AnnouncementGap DownHigh Trading VolumeCELUCelularity0.7239 of 5 stars$3.84+1.3%$6.00+56.3%-17.2%$90.77M$54.22M-1.45220Earnings ReportGap Down Related Companies and Tools Related Companies ANIX Competitors SRZN Competitors CRDL Competitors XBIT Competitors VTGN Competitors VIRI Competitors IMUX Competitors ABOS Competitors EPIX Competitors CELU Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FBLG) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A new set of 7 AI stocks are DOMINATING the market. Here’s why one financial guru says they could be the mo...The Oxford Club | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FibroBiologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share FibroBiologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
